WallStSmart

Stryker Corporation (SYK)vsWORK Medical Technology Group LTD Ordinary Shares (WOK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Stryker Corporation generates 254918% more annual revenue ($25.12B vs $9.85M). SYK leads profitability with a 12.9% profit margin vs -10.9%. SYK earns a higher WallStSmart Score of 65/100 (C+).

SYK

Buy

65

out of 100

Grade: C+

Growth: 8.0Profit: 7.5Value: 9.3Quality: 7.0
Piotroski: 3/9Altman Z: 2.18

WOK

Avoid

29

out of 100

Grade: F

Growth: 2.0Profit: 2.0Value: 5.0Quality: 7.0
Piotroski: 4/9Altman Z: 1.82
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

SYKUndervalued (+16.8%)

Margin of Safety

+16.8%

Fair Value

$393.59

Current Price

$327.65

$65.94 discount

UndervaluedFair: $393.59Overvalued

Intrinsic value data unavailable for WOK.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

SYK4 strengths · Avg: 8.8/10
EPS GrowthGrowth
55.9%10/10

Earnings expanding 55.9% YoY

Market CapQuality
$125.72B9/10

Large-cap with strong market position

Operating MarginProfitability
27.2%8/10

Strong operational efficiency at 27.2%

Free Cash FlowQuality
$1.88B8/10

Generating 1.9B in free cash flow

WOK1 strengths · Avg: 10.0/10
Price/BookValuation
0.1x10/10

Reasonable price relative to book value

Areas to Watch

SYK3 concerns · Avg: 3.7/10
PEG RatioValuation
1.604/10

Expensive relative to growth rate

P/E RatioValuation
39.1x4/10

Premium valuation, high expectations priced in

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

WOK4 concerns · Avg: 2.8/10
Altman Z-ScoreHealth
1.824/10

Grey zone — moderate risk

Market CapQuality
$1.46M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-6.5%2/10

ROE of -6.5% — below average capital efficiency

Revenue GrowthGrowth
-14.4%2/10

Revenue declined 14.4%

Comparative Analysis Report

WallStSmart Research

Bull Case : SYK

The strongest argument for SYK centers on EPS Growth, Market Cap, Operating Margin. Revenue growth of 11.4% demonstrates continued momentum.

Bull Case : WOK

The strongest argument for WOK centers on Price/Book.

Bear Case : SYK

The primary concerns for SYK are PEG Ratio, P/E Ratio, Piotroski F-Score.

Bear Case : WOK

The primary concerns for WOK are Altman Z-Score, Market Cap, Return on Equity.

Key Dynamics to Monitor

SYK profiles as a value stock while WOK is a turnaround play — different risk/reward profiles.

SYK is growing revenue faster at 11.4% — sustainability is the question.

SYK generates stronger free cash flow (1.9B), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

SYK scores higher overall (65/100 vs 29/100) and 11.4% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Stryker Corporation

HEALTHCARE · MEDICAL DEVICES · USA

Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.

Visit Website →

WORK Medical Technology Group LTD Ordinary Shares

HEALTHCARE · MEDICAL DEVICES · USA

WORK Medical Technology Group Ltd is a prominent player in the medical technology sector, specializing in the research, development, and commercialization of innovative healthcare solutions. The company focuses on creating advanced medical devices that significantly improve patient outcomes and meet pressing global healthcare challenges. With a strong dedication to quality and a diverse product portfolio, WORK is strategically positioned for sustained growth, making it an appealing investment choice for institutional investors aiming to capitalize on transformative developments in the healthcare industry.

Visit Website →

Want to dig deeper into these stocks?